Loading...
Market
When will the EMA approve Rezdiffra?
2
Resolution / Starting Odds
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 or later • 25%
Official EMA announcements
Story
Madrigal's Rezdiffra Launches Strongly with $14.6M Sales
Aug 7, 2024, 08:04 PM
Madrigal Pharmaceuticals has reported a successful launch of its new drug, Rezdiffra, which is the first approved treatment for MASH (Metabolic Associated Steatohepatitis). In the second quarter of 2024, Rezdiffra achieved net sales of $14.6 million, exceeding expectations. The company has secured coverage for more than 50% of commercial patients, with less than 5% requiring a liver biopsy. The launch is expected to gain momentum, with plans to reduce the time to fill prescriptions from 60 days to 30 days by the end of the next quarter. Additionally, Madrigal is preparing for potential EMA approval in 2025.
View original story
Similar markets
Yes • 50%
No • 50%
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Approval delayed • 25%
Not approved • 25%
